Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
- Authors
- Hur, Joon Young; Ku, Bo Mi; Shim, Joon Ho; Jung, Hyun Ae; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju
- Issue Date
- May-2020
- Publisher
- INT INST ANTICANCER RESEARCH
- Keywords
- Crizotinib; MET Exon 14 Skipping; NSCLC
- Citation
- IN VIVO, v.34, no.3, pp.1399 - 1406
- Indexed
- SCIE
SCOPUS
- Journal Title
- IN VIVO
- Volume
- 34
- Number
- 3
- Start Page
- 1399
- End Page
- 1406
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190697
- DOI
- 10.21873/invivo.11920
- ISSN
- 0258-851X
- Abstract
- Background/Aim: MET exon 14 skipping occurs in 3-4% of patients with lung adenocarcinomas. In this study, we performed a comprehensive analysis of clinical data from Korean non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping. Patients and Methods: Overall, 1,020 patients diagnosed with NSCLC between January 2015 and July 2017 were analyzed by next-generation sequencing. Results: MET exon 14 skipping was identified in 20 NSCLC patients (1.9%). The median age was 69 years (range=39-86 years), 60.0% were male, and most (55.0%) were ever-smokers. For first-line chemotherapy, the median overall survival was 9.5 months and progression free survival was 4.0 months, respectively. Twelve patients received pemetrexed-based chemotherapy and the overall response rate was 33.3% (4/12). Among four crizotinib-treated patients, one continued therapy for 8 months with the best response being disease stability. Conclusion: Given the poor clinical outcome and response to therapy for NSCLC, and the availability of promising anti-tumor MET inhibitors, screening for the MET exon 14 skip mutation should be incorporated into clinical practice.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190697)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.